article thumbnail

Why is the market design for innovative pharmaceuticals not well understood?

Healthcare ECONOMIST

A lot of people when they look at pharmaceutical prices think they are ‘too high’ or ‘too low’ But the question is, too high or too low relative to what? What are our goals in pharmaceutical pricing. That is the title of a fantastic editorial from Olivença et al.

article thumbnail

Teva Pharmaceuticals, collaborators team up to donate behavioral health meds to free clinics, pharmacies

Fierce Healthcare

Teva Pharmaceuticals, collaborators team up to donate behavioral health meds to free clinics, pharmacies agliadkovskaya Thu, 05/04/2023 - 14:30

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

AstraZeneca Acquires Fusion Pharmaceuticals for $2B to Bolster Radioconjugate Pipeline

HIT Consultant

What You Should Know: AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs).

article thumbnail

European Union Pharmaceutical Package: A Summary

Healthcare ECONOMIST

Today I’m turning this post over to some of my FTI colleagues in Europe ( Antoine Mialhe , Katja Murray and Valeria Fagone among others) who helped summarize the Reform of the EU pharmaceutical legislation that the European Union (EU) adopted on April 26, 2023. A more detailed analysis is in the PDF link below.

article thumbnail

Out-of-pocket spending on prescriptions grew even after accounting for rebates: study

Fierce Healthcare

There's no shortage of attention on rising pharmaceutical costs, but policymakers need to have the full picture of trends in this space to work off of, according to a new study.

article thumbnail

BenchSci Launches ‘Map’ of Biology Research Platform for Pharmaceutical Research

HIT Consultant

Two major pharmaceutical companies are currently beta testing it, putting them at the forefront of leveraging AI enterprise-wide to advance new medicines for patients most in need. It’s not simply the proprietary AI that’s revolutionary.

article thumbnail

Diffusion of pharmaceuticals and the patient’s influence

Healthcare ECONOMIST

Through what mechanisms are patients and physicians made aware of new pharmaceuticals and decide to prescribe them. It is well known that physician peer networks often help share information about new pharmaceuticals including clinical information as well as the providers own experience using the new treatment.